Direct oral anticoagulants (DOACs) are used to prevent ischemic stroke in patients with atrial fibrillation (AF), but a significant risk of bleeds limit their use. Some patients refuse or are unable to adhere to this treatment. As 90% of AF-related thrombi originate in the left atrial appendage, its percutaneous or surgical closure (LAAC) emerged as an alternative.1 Though percutaneous LAAC is technically feasible, its exact place compared to DOAC remains unsettled.
Rod Passman
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Rod
Contact Rod, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack